- Home
- VTYX vs CGEN Comparison
VTYX vs CGEN Comparison
Compare VTYX & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- CGEN
- Stock Information
- Founded
- VTYX 2018
- CGEN 1993
- Country
- VTYX United States
- CGEN Israel
- Employees
- VTYX N/A
- CGEN N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VTYX Health Care
- CGEN Health Care
- Exchange
- VTYX Nasdaq
- CGEN Nasdaq
- Market Cap
- VTYX 154.9M
- CGEN 167.4M
- IPO Year
- VTYX 2021
- CGEN 2000
- Fundamental
- Price
- VTYX $2.58
- CGEN $1.46
- Analyst Decision
- VTYX Buy
- CGEN
- Analyst Count
- VTYX 4
- CGEN 0
- Target Price
- VTYX $11.33
- CGEN N/A
- AVG Volume (30 Days)
- VTYX 1.1M
- CGEN 245.6K
- Earning Date
- VTYX 08-15-2025
- CGEN 08-06-2025
- Dividend Yield
- VTYX N/A
- CGEN N/A
- EPS Growth
- VTYX N/A
- CGEN N/A
- EPS
- VTYX N/A
- CGEN N/A
- Revenue
- VTYX N/A
- CGEN $27,589,000.00
- Revenue This Year
- VTYX N/A
- CGEN N/A
- Revenue Next Year
- VTYX N/A
- CGEN $105.77
- P/E Ratio
- VTYX N/A
- CGEN N/A
- Revenue Growth
- VTYX N/A
- CGEN N/A
- 52 Week Low
- VTYX $0.78
- CGEN $1.13
- 52 Week High
- VTYX $3.39
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- VTYX 46.35
- CGEN 37.69
- Support Level
- VTYX $2.63
- CGEN $1.35
- Resistance Level
- VTYX $2.92
- CGEN $1.50
- Average True Range (ATR)
- VTYX 0.22
- CGEN 0.08
- MACD
- VTYX -0.08
- CGEN -0.01
- Stochastic Oscillator
- VTYX 0.00
- CGEN 37.93
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.